United Therapeutics Corp (UTHR) 151.11 $UTHR
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
Hot Growth Stocks: What Sectors Lead 2015 Now?
at Investor's Business Daily - Thu Feb 05, 5:32PM CST
Think big themes. The list of YWR stocks is a statement on just that. Which companies are growing rapidly? What are the most dynamic business sectors of the economy? The Your Weekly Review tries to objectively answer those questions. If you're new to...
AKRX: 47.28 (-0.25), UTHR: 151.11 (+3.59), MSCC: 30.87 (+0.06), TSM: 24.84 (+0.37), LUV: 43.30 (-0.20)
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics
PR Newswire - Wed Feb 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Celgene Corporation (NASDAQ: CELG), CytRx Corporation (NASDAQ: CYTR), Amicus Therapeutics Inc. (NASDAQ: FOLD), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on ARIAD Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=ARIAD%20P...amp;s=ARIA. On Tuesday, February 03, 2015, the NASDAQ Composite ended at 4,727.74, up 1.09%, the Dow Jones Industrial Average advanced 1.76%, to finish the day at 17,666.40, and the S&P 500 closed at 2,050.03, up 1.44%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 811.48, up 0.65%, with the index also advancing 4.16% in the previous three months. Register for your complimentary reports at the links given below.
UTHR: 151.11 (+3.59), CYTR: 2.96 (+0.23), ARIA: 7.35 (+0.45), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
United Therapeutics Rises 3.82% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jan 20, 5:38PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $140.93 to a high of $148.19. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $141.31 on volume of 868,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 151.11 (+3.59)
United Therapeutics Clears Hypertension Drug Hurdles
at Investor's Business Daily - Fri Jan 16, 5:44PM CST
Blockbuster drugs can reap huge profits for branded drugmakers, but sales can drop sharply when patents expire and copycat versions come to market. United Therapeutics (UTHR) faces those challenges too. But it recently scored a victory in a...
GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), UTHR: 151.11 (+3.59), NVS: 102.20 (-0.17)
Ulta Among IBD 50 Stocks Setting Up In Shaky Market
at Investor's Business Daily - Fri Jan 16, 5:44PM CST
The stock market so far in 2015 calls for wariness on the part of investors. As during much of 2014, leading stocks break out, then move sideways, or a breakout fails and the stock heads south. But this week's edition of the IBD 50 list does include...
BCC: 42.88 (+0.26), PRXL: 62.91 (-0.18), UTHR: 151.11 (+3.59), IDXX: 159.08 (+1.72), ULTA: 136.66 (+0.59), AAPL: 127.08 (+0.62)
United Therapeutics Set to Possibly Pullback After Yesterday's Rally of 2.36%
Comtex SmarTrend(R) - Fri Jan 16, 4:53PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $137.40 to a high of $141.31. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $139.24 on volume of 771,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 151.11 (+3.59)
Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 1:20PM CST
Arena Pharmaceuticals, Inc. (ARNA) recently announced that it has initiated patient dosing in a phase II clinical trial on pipeline candidate, ralinepag.
UTHR: 151.11 (+3.59), ARNA: 4.55 (+0.02), RGDO: 1.17 (+0.02)
Biotech Stock United Therapeutics Tests New Buy Point
at Investor's Business Daily - Thu Jan 15, 11:50AM CST
While the market has been ailing in recent days, United Therapeutics (UTHR) has shown healthy action, climbing past a 137.03 breakout in early Thursday trading. While the market has been ailing in recent days, United Therapeutics (UTHR) has shown...
UTHR: 151.11 (+3.59)
Comparing America's 3 Largest Drug Manufacturers/Other Companies
Joseph Cafariello - at Seeking Alpha - Mon Jan 12, 8:20AM CST
AGN: 229.49 (+1.87), ISIS: 63.86 (-0.43), UTHR: 151.11 (+3.59)
United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Tue Jan 06, 8:50PM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Co-Chief Executive Officer, and Roger Jeffs, Ph.D., President and Co-Chief Executive Officer, of United Therapeutics will provide an overview and update on the company's business at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
JPM: 59.67 (+0.10), UTHR: 151.11 (+3.59)
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 1.36% Loss
Comtex SmarTrend(R) - Fri Jan 02, 4:37PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $125.00 to a high of $130.13. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $129.25 on volume of 588,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 151.11 (+3.59)
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 1.36% Sell Off
Comtex SmarTrend(R) - Fri Jan 02, 4:37PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $125.00 to a high of $130.13. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $129.25 on volume of 588,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 151.11 (+3.59)
United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 75.26 (+0.33), UTHR: 151.11 (+3.59)
My 2015 Stock Picks And Big Trends
Leigh Drogen - at Seeking Alpha - Wed Dec 31, 3:45PM CST
As always, a small caveat regarding my 10 stocks picks for the year. Nowhere outside of these yearly posts would I ever pick a single stock under the assumption that you must hold it the entire year - that's just insane. The only risk management...
UA: 73.76 (-0.19), RDWR: 20.85 (+0.42), ECHO: 26.72 (+0.35), ZLTQ: 34.48 (+0.28), OTEX: 61.19 (+0.99), LOGM: 52.22 (+4.17), FB: 75.74 (-0.49), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), QLYS: 47.95 (+1.46), TNET: 36.49 (+0.76)
United Therapeutics Announces Signing Of Agreement For New Remodulin Delivery System
PR Newswire - Wed Dec 31, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today the signing of an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin® (treprostinil) Injection to patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system.
UTHR: 151.11 (+3.59)
United Therapeutics progresses on expanded label for Remodulin
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:13AM CST
MDT: 75.26 (+0.33), UTHR: 151.11 (+3.59)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
Hot Growth Stocks: What Sectors Lead 2015 Now?
at Investor's Business Daily - Thu Feb 05, 5:32PM CST
Think big themes. The list of YWR stocks is a statement on just that. Which companies are growing rapidly? What are the most dynamic business sectors of the economy? The Your Weekly Review tries to objectively answer those questions. If you're new to...
AKRX: 47.28 (-0.25), UTHR: 151.11 (+3.59), MSCC: 30.87 (+0.06), TSM: 24.84 (+0.37), LUV: 43.30 (-0.20)
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics
PR Newswire - Wed Feb 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Celgene Corporation (NASDAQ: CELG), CytRx Corporation (NASDAQ: CYTR), Amicus Therapeutics Inc. (NASDAQ: FOLD), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on ARIAD Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=ARIAD%20P...amp;s=ARIA. On Tuesday, February 03, 2015, the NASDAQ Composite ended at 4,727.74, up 1.09%, the Dow Jones Industrial Average advanced 1.76%, to finish the day at 17,666.40, and the S&P 500 closed at 2,050.03, up 1.44%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 811.48, up 0.65%, with the index also advancing 4.16% in the previous three months. Register for your complimentary reports at the links given below.
UTHR: 151.11 (+3.59), CYTR: 2.96 (+0.23), ARIA: 7.35 (+0.45), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
United Therapeutics Rises 3.82% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jan 20, 5:38PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $140.93 to a high of $148.19. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $141.31 on volume of 868,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 151.11 (+3.59)
United Therapeutics Clears Hypertension Drug Hurdles
at Investor's Business Daily - Fri Jan 16, 5:44PM CST
Blockbuster drugs can reap huge profits for branded drugmakers, but sales can drop sharply when patents expire and copycat versions come to market. United Therapeutics (UTHR) faces those challenges too. But it recently scored a victory in a...
GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), UTHR: 151.11 (+3.59), NVS: 102.20 (-0.17)
Ulta Among IBD 50 Stocks Setting Up In Shaky Market
at Investor's Business Daily - Fri Jan 16, 5:44PM CST
The stock market so far in 2015 calls for wariness on the part of investors. As during much of 2014, leading stocks break out, then move sideways, or a breakout fails and the stock heads south. But this week's edition of the IBD 50 list does include...
BCC: 42.88 (+0.26), PRXL: 62.91 (-0.18), UTHR: 151.11 (+3.59), IDXX: 159.08 (+1.72), ULTA: 136.66 (+0.59), AAPL: 127.08 (+0.62)
United Therapeutics Set to Possibly Pullback After Yesterday's Rally of 2.36%
Comtex SmarTrend(R) - Fri Jan 16, 4:53PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $137.40 to a high of $141.31. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $139.24 on volume of 771,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 151.11 (+3.59)
Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 1:20PM CST
Arena Pharmaceuticals, Inc. (ARNA) recently announced that it has initiated patient dosing in a phase II clinical trial on pipeline candidate, ralinepag.
UTHR: 151.11 (+3.59), ARNA: 4.55 (+0.02), RGDO: 1.17 (+0.02)
Biotech Stock United Therapeutics Tests New Buy Point
at Investor's Business Daily - Thu Jan 15, 11:50AM CST
While the market has been ailing in recent days, United Therapeutics (UTHR) has shown healthy action, climbing past a 137.03 breakout in early Thursday trading. While the market has been ailing in recent days, United Therapeutics (UTHR) has shown...
UTHR: 151.11 (+3.59)
Comparing America's 3 Largest Drug Manufacturers/Other Companies
Joseph Cafariello - at Seeking Alpha - Mon Jan 12, 8:20AM CST
AGN: 229.49 (+1.87), ISIS: 63.86 (-0.43), UTHR: 151.11 (+3.59)
United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Tue Jan 06, 8:50PM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Co-Chief Executive Officer, and Roger Jeffs, Ph.D., President and Co-Chief Executive Officer, of United Therapeutics will provide an overview and update on the company's business at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
JPM: 59.67 (+0.10), UTHR: 151.11 (+3.59)
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 1.36% Loss
Comtex SmarTrend(R) - Fri Jan 02, 4:37PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $125.00 to a high of $130.13. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $129.25 on volume of 588,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 151.11 (+3.59)
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 1.36% Sell Off
Comtex SmarTrend(R) - Fri Jan 02, 4:37PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $125.00 to a high of $130.13. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $129.25 on volume of 588,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 151.11 (+3.59)
United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 75.26 (+0.33), UTHR: 151.11 (+3.59)
My 2015 Stock Picks And Big Trends
Leigh Drogen - at Seeking Alpha - Wed Dec 31, 3:45PM CST
As always, a small caveat regarding my 10 stocks picks for the year. Nowhere outside of these yearly posts would I ever pick a single stock under the assumption that you must hold it the entire year - that's just insane. The only risk management...
UA: 73.76 (-0.19), RDWR: 20.85 (+0.42), ECHO: 26.72 (+0.35), ZLTQ: 34.48 (+0.28), OTEX: 61.19 (+0.99), LOGM: 52.22 (+4.17), FB: 75.74 (-0.49), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), QLYS: 47.95 (+1.46), TNET: 36.49 (+0.76)
United Therapeutics Announces Signing Of Agreement For New Remodulin Delivery System
PR Newswire - Wed Dec 31, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today the signing of an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin® (treprostinil) Injection to patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system.
UTHR: 151.11 (+3.59)
United Therapeutics progresses on expanded label for Remodulin
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:13AM CST
MDT: 75.26 (+0.33), UTHR: 151.11 (+3.59)
